LANZAJET EXPANDS PARTNERSHIP WITH MICROSOFT TO STRENGTHEN THE COMPANY'S GLOBAL GROWTH
CHICAGO, June 12, 2025 /CNW/ -- LanzaJet, Inc., a leading next-gen fuels technology company and producer of sustainable fuels, today announced a new agreement with Microsoft to adopt Microsoft Azure as the company's preferred cloud platform. The agreement marks an expansion of LanzaJet's partnership with Microsoft and underscores the central role innovation plays in scaling next-generation fuels for aviation.
LanzaJet will leverage Azure to support their global growth by enhancing the company's operational systems, financial platforms, and data-driven decision-making capabilities, including those related to plant performance and supply chain optimization.
"For early-stage technology companies like LanzaJet, partners matter, and Microsoft has been with us from the start," said Anne Sidio, Chief Transformation Officer at LanzaJet. "This agreement builds on a multi-level relationship with Microsoft, from early investment in our company to renewable fuel offtake agreements and now digital infrastructure, reflecting the kind of collaboration needed to accelerate innovation, scale operations, and build a secure and resilient global platform."
Microsoft has been a cornerstone partner in LanzaJet's journey, providing both capital and commercial alignment. The Microsoft Climate Innovation Fund was among the first institutions to invest in LanzaJet, offering one of the company's earliest low-interest loans to help finance the construction of LanzaJet Freedom Pines Fuels, the world's first commercial ethanol-to-SAF facility in Soperton, Georgia. Microsoft deepened that commitment in 2024 with a direct investment in LanzaJet to support continued global deployment of its technology.
In addition to financial backing, Microsoft is also an offtaker of LanzaJet's fuels, leveraging renewable diesel as well as SAF Certificates (SAFc) from future LanzaJet projects to advance its own emissions reduction goals and fulfill its industry-leading sustainability commitments, including becoming carbon negative by 2030. With today's announcement, Microsoft becomes a core technology partner supporting LanzaJet's internal systems as the company scales its global operations.
"Microsoft's continued support of LanzaJet reinforces the critical role enterprise-grade technology can play in climate innovation," said Alistair Speirs, Senior Director of Azure Global Infrastructure at Microsoft. "We are glad to be partnering with a leader in the sustainable fuels industry and be a part of LanzaJet's continued mission to decarbonize aviation."
As LanzaJet expands its project portfolio across the U.S., Europe, Asia, and Latin America, building their global platform on Azure will enable secure, scalable connectivity across regions, while supporting robust data management in areas ranging from feedstock traceability to emissions accounting.
This announcement follows a series of milestones for LanzaJet, including recent recognition from TIME100, S&P Global, and Reuters for the company's innovation, impact, and leadership in the global clean energy transition.
LanzaJet is a leading alternative fuels technology provider with patented ethanol-based alcohol-to-jet (ATJ) technology. LanzaJet is creating an opportunity for future generations by accelerating the production and deployment of Sustainable Aviation Fuel (SAF) and other alternative fuel technologies critical to transform the global economy. LanzaJet was recently named TIME100 Most Influential Companies for 2024 and a Rising Star Company of the Year by S&P Global. Further information is available at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
40 minutes ago
- Cision Canada
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both federal and state levels, casting a shadow over ongoing cancer research efforts. Meanwhile, the incidence of cancers—especially gastrointestinal and colorectal cancers among younger populations—is on the rise, heightening the need for new therapeutic approaches. In response, a new generation of biotech companies is stepping forward with promising clinical milestones on the horizon, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zai Lab Limited (NASDAQ: ZLAB), GeoVax Labs, Inc. (NASDAQ: GOVX), OS Therapies (NYSE-American: OSTX), and SELLAS Life Sciences Group, Inc. (NASDAQ: SLS). Industry forecasts suggest the global oncology drug market could climb past US$900 billion by 2034. Within that, next-generation cancer treatments —powered by advances in personalized and precision medicine—are expected to reach US$175.2 billion, according to Precedence Research, growing at a compound annual rate of 7.35%. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) just rolled out an expanded translational data review package that tightens the scientific case for pelareorep, its intravenously delivered oncolytic virus. Fresh analyses from the GOBLET gastrointestinal‑cancer study and the AWARE‑1 breast‑cancer study shows pelareorep actively replicating inside tumors, switching on interferon signaling in the immune system, and drawing tumor‑infiltrating lymphocytes into the cancer microenvironment. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Investigators also recorded a clear increase in PD‑L1 expression, a checkpoint marker that helps immune cells recognize tumors, and tracked newly expanded T‑cell clones in the blood that matched those inside shrinking lesions. Together, these findings suggest pelareorep can convert "cold" tumors into "hot" ones that respond better to modern immunotherapies. "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, CEO of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." Two GOBLET cohorts—metastatic pancreatic ductal adenocarcinoma (mPDAC) and anal cancer—remain open. Management plans to outline the next clinical milestones before the end of the third quarter. Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a two‑year overall‑survival rate of 21.9%, compared with the historical benchmark of 9.2%. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective response rate. No immune checkpoint therapy is approved in this cancer today, which makes the signal especially noteworthy. Progress extends to hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC). Across two randomized trials, pelareorep added more than ten months of median overall survival. In BRACELET‑1, the drug nearly doubled median progression‑free survival to 12.1 months versus 6.4 months in the control arm, suggesting durable disease control. Next week, Oncolytics will host a KOL webinar on July 22 featuring leading GI and immuno-oncology experts to discuss pelareorep's data and positioning in pancreatic and gastrointestinal cancers. Participating physicians include the GOBLET trial's primary investigator as well as global leaders in immunotherapy and clinical trial design, underscoring the growing interest in pelareorep's mechanism and outcomes. To steer these data toward value‑creating deals and late‑stage trials, Oncolytics Biotech strengthened its leadership earlier this year. The board tapped industry veteran Jared Kelly for the CEO seat and named Andrew Aromando Chief Business Officer. Both executives helped guide Ambrx Biopharma into a $2‑billion sale to Johnson & Johnson, giving them a playbook for capital‑efficient development and strategic partnering. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Pelareorep currently holds FDA Fast Track designation in both mPDAC (pancreatic cancer) and HR+/HER2- mBC (breast cancer), with Orphan Drug status for pancreatic cancer in the U.S. and Europe. In other recent industry developments and happenings in the market include: Zai Lab Limited (NASDAQ: ZLAB) recently reported that its Phase 3 FORTITUDE‑101 study found bemarituzumab plus mFOLFOX6 significantly improved overall survival over chemotherapy alone in first‑line fibroblast growth factor receptor 2b (FGFR2b)‑positive gastric and gastroesophageal junction cancers. The antibody becomes the first FGFR2b inhibitor to post a statistically and clinically meaningful survival benefit, and the company plans a rapid regulatory filing in China under its Breakthrough Therapy designation. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." GeoVax Labs, Inc. (NASDAQ: GOVX) recently stated that the FDA's curative‑intent approval of Keytruda for head and neck cancer strengthens the rationale for its planned Phase 2 trial combining Gedeptin and pembrolizumab. "We believe Gedeptin's tumor-targeted cytotoxicity can enhance immunotherapy efficacy, particularly in the perioperative window where anti-tumor immunity can be primed," added Dr. Kelly McKee, GeoVax's Chief Medical Officer. "We are excited to embark on the next phase of Gedeptin development as we attempt to build on the important advances being made in this disease." The study, expected to launch in 2026, will give Gedeptin intratumorally before surgery to trigger local cytotoxicity, then add checkpoint inhibition to boost systemic immunity. Endpoints include pathologic response, recurrence rates, and immune biomarkers, aligning with guidance in a recent New England Journal of Medicine editorial. OS Therapies (NYSE-American: OSTX) has locked in an End‑of‑Phase 2 FDA meeting for 27 August 2025 to discuss a rolling Biologics License Application for OST‑HER2 in recurrent, lung‑metastatic osteosarcoma, while parallel regulatory consultations are set with the EMA and the UK MHRA. "We are making significant progress towards our primary objective of obtaining regulatory approval for OST-HER2 in recurrent, pulmonary metastatic osteosarcoma prior to the sunsetting of the rare pediatric disease priority review voucher ("PRV") program," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "We strongly believe in the promise of the listeria immunotherapy platform to help prevent and treat cancer, and intend to judiciously deploy our capital to focus on the OST-HER2 approval while advancing our other clinical programs without deploying significant capital or running other clinical studies while we wait for the OST-HER2 approval and related PRV sale." The company is also advancing a Phase 1 prostate‑cancer immunotherapy, OST‑504, with full data expected later in 2025. OST‑HER2 already carries Rare Pediatric Disease, Fast Track, and Orphan Drug designations, positioning the program for a potential Priority Review Voucher and accelerated approvals in multiple markets. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) met every primary endpoint in its Phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia-myelodysplasia-related changes (AML MR), delivering a 44% overall response rate at the optimal 30 mg twice‑weekly dose and a median overall survival of 8.9 months—far above the 2.4 month historical benchmark. The CDK9 inhibitor also showed a 50% response rate in high‑risk ASXL1‑mutated and M4/M5 subgroups, with no dose‑limiting toxicities reported. "We are excited to report that our Phase 2 trial met all key endpoints, with clinical responses and survival outcomes that exceed targeted expectations and historical benchmarks," said Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS. "AML remains an area of urgent unmet medical need, particularly for patients with relapsed or refractory disease, where standard treatments are often ineffective and poorly tolerated. What sets SLS009 apart is its consistent efficacy across a broad range of molecular subtypes." Following FDA guidance, the company will launch an 80‑patient randomized study in newly diagnosed first‑line AML by Q1 2026 to support a potential New Drug Application. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
40 minutes ago
- Cision Canada
RIOT PLATFORMS, INC. REPORTS BENEFICIAL OWNERSHIP OF 9.85% IN BITFARMS LTD.
CASTLE ROCK, Colo., July 16, 2025 /CNW/ - Riot Platforms, Inc. (" Riot") issues this press release pursuant to Part 3 of Canadian National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and Part 5 of Canadian National Instrument 62-104 – Take-Over Bids and Issuer Bids in respect of Bitfarms Ltd. (" Company"). Riot announces that on July 16, 2025 it sold 2,462,458 common shares (the " Sold Shares") of the Company representing approximately 0.44% of the issued and outstanding Common Shares (the " Common Shares") of the Company (based on the information contained in the Company's management information circular filed on June 9, 2025 (the " Company's Circular"). The Sold Shares were sold through normal course sales on the Nasdaq Stock Market and other open market trades for a weighted average price of approximately US$1.05 per Sold Share (equivalent to approximately C$1.44 per Sold Share based on the daily exchange rate posted by the Bank of Canada on July 16, 2025 (the " Exchange Rate")) at a price range per Sold Share of approximately US$1.04 to US$1.07 (equivalent to approximately C$1.43 to C$1.46 based on the Exchange Rate) for an aggregate amount equal to US$2,593,460.77 (equivalent to approximately C$3,556,153.40 based on the Exchange Rate). Immediately prior to the sales of Common Shares giving rise to the issuance of this press release, Riot beneficially owned 57,207,521 Common Shares, representing approximately 10.29% of the issued and outstanding Common Shares (based on the information contained in the Company's Circular). Following completion of the aforementioned sales, Riot beneficially owned 54,745,063 Common Shares, representing approximately 9.85% of the issued and outstanding Common Shares as at the date hereof (based on the information contained in the Company's Circular). Riot intends to review its investment in the Company on a continuing basis and depending upon various factors, including without limitation, any discussion between Riot, the Company and/or the Company's Board of Directors and its advisors regarding, among other things, the Company's financial position and strategic direction, overall market conditions, other investment opportunities available to Riot, and the availability of securities of the Company at prices that would make the purchase or sale of such securities desirable, Riot may (i) increase or decrease its position in the Company through, among other things, the purchase or sale of securities of the Company, including through transactions involving the Common Shares and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Company in the open market or otherwise, (ii) enter into transactions that increase or hedge its economic exposure to the Common Shares without affecting its beneficial ownership of the Common Shares or (iii) consider or propose one or more of the actions described in subparagraphs (a) - (k) of Item 5 of Riot's early warning report filed in accordance with applicable Canadian securities laws. This press release is not meant to be, nor should it be construed as, an offer (or an intention to make an offer) to buy or the solicitation of an offer to sell any of the Company's securities. Riot will file the Early Warning Report in accordance with applicable securities laws, which will be available under the Company's profile at The head office of the Company is 110 Yonge Street, Suite 1601 Toronto, Ontario M5C 1T4. The address of Riot is 3855 Ambrosia Street, Suite 301, Castle Rock, CO 80109. FOR MORE INFORMATION For further information and to obtain a copy of the Early Warning Report, please see the Company's profile on the SEDAR+ website ( or contact Phil McPherson, Vice President, Capital Markets & Investor Relations, at (303) 794-2000 ext. 110. About Riot Platforms, Inc. Riot's (NASDAQ: RIOT) vision is to be the world's leading Bitcoin-driven infrastructure platform. Our mission is to positively impact the sectors, networks, and communities that we touch. We believe that the combination of an innovative spirit and strong community partnership allows the Company to achieve best-in-class execution and create successful outcomes. Riot, a Nevada corporation, is a Bitcoin mining and digital infrastructure company focused on a vertically integrated strategy. Riot has Bitcoin mining operations in central Texas and Kentucky, and electrical engineering and fabrication operations in Denver, Colorado, and Houston, Texas. For more information, visit Cautionary Note Regarding Forward Looking Statements Statements contained herein that are not historical facts constitute "forward-looking statements" and "forward-looking information" (together, "forward-looking statements") within the meaning of applicable U.S. and Canadian securities laws that reflect management's current expectations, assumptions, and estimates of future events, performance and economic conditions. Such forward-looking statements rely on the safe harbor provisions of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 and the safe harbor provisions of applicable Canadian securities laws. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words and phrases such as "anticipate," "believe," "create," "drive," "expect," "forecast," "future," "growth," "intend," "hope," "opportunity," "plan," "potential," "proposal," "synergies," "unlock," "upside," "will," "would," and similar words and phrases are intended to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance or actual results, and readers should not place undue reliance on any forward-looking statement as actual results may differ materially and adversely from forward-looking statements. Detailed information regarding the factors identified by the management of Riot, which they believe may cause actual results to differ materially from those expressed or implied by such forward-looking statements in this press release, may be found in Riot's filings with the U.S. Securities and Exchange Commission (the " SEC"), including the risks, uncertainties and other factors discussed under the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" of Riot's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 28, 2025, and the other filings Riot has made or will make with the SEC after such date, copies of which may be obtained from the SEC's website at All forward-looking statements contained herein are made only as of the date hereof, and Riot disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which Riot hereafter becomes aware, except as required by applicable law.
Cision Canada
3 hours ago
- Cision Canada
Determined to Work Together for Jasper: Parks Canada and Partners Bolster Safe and Swift Return Home Français
New financial support will enable remediation efforts and help Jasper residents return home safely and swiftly. JASPER, AB, July 16, 2025 /CNW/ - One year after the Jasper Wildfire forced residents from their homes, Parks Canada, the Municipality of Jasper, the Canadian Red Cross, and Prairies Economic Development Canada continue to work as partners in the recovery and rebuild of Jasper, with a shared focus on quickly returning residents to safe and permanent homes. Today, Parks Canada and the Canadian Red Cross jointly announced up to $5 million in additional support for Jasper residents. This will be intended for Jasperites who require contaminated soil testing and removal prior to rebuilding permanent housing. This new funding will ensure a swift, safe and dignified path forward for those most impacted. New financial assistance, administered by the Canadian Red Cross, will provide support to residents for uninsured costs related to soil remediation and testing that will ensure the long-term health of residents. The Government of Canada, through Parks Canada and other federal partners, has invested more than $180 million in rebuilding Jasper, and the work continues. Together, we have: expedited reconstruction efforts through streamlined processes to make rebuilding as efficient as possible; secured interim housing for 300 Jasper families to allow them to return to the community as soon as possible; coordinated debris removal on 100 per cent of affected lots; and welcomed a number of residents back to permanent housing. With debris removal complete and development permits issued through a streamlined process, the focus has now shifted to soil remediation and ensuring the future health of residents. Parks Canada is continuing to work closely with homeowners to provide clear and timely information, practical solutions, and flexibility throughout this phase. A coordinated plan to guide expedited soil remediation efforts and support residents will be shared very soon. We remain focussed on quickly getting building permits for residents who lost their homes and businesses so that they can move forward with their lives. Together, these efforts reflect a shared commitment to helping Jasper rebuild stronger and faster, with the well-being of residents at the heart of every decision. Quotes "The residents of Jasper have shown remarkable strength during this difficult time. Their resilience and solidarity remind us that, together, we're not just rebuilding homes, but restoring hope. We are here to support them every step of the way to rebuild the town quickly and safely so that Jasperites can move towards building a stronger future." The Honourable Steven Guilbeault Minister of Canadian Identity and Culture and Minister responsible for Official Languages " Our new government continues to work with its partners to ensure residents can return to their permanent homes in a safe and timely manner. As Canada's first-ever Minister for Community Resilience, I'm proud to be part of a government that's committed to helping communities like Jasper recover and thrive." The Honourable Eleanor Olszewski Minister of Emergency Management and Community Resilience and Minister responsible for Prairies Economic Development Canada. "On behalf of so many of our residents, I extend sincere gratitude to Parks Canada, the Government of Canada, and the Canadian Red Cross for their continued commitment and support. Their thoughtful, coordinated approach to easing the financial and emotional burden of this difficult time has made a meaningful difference in the lives of those rebuilding. This support is helping our community move forward — together." Richard Ireland Mayor of Jasper "The Canadian Red Cross commends Parks Canada for providing financial support that addresses soil remediation which has been an ongoing barrier for rebuilding homes in Jasper. The Canadian Red Cross continues to work alongside community and government partners to support recovery in Jasper and will be there to address ongoing and evolving needs in the weeks and months to come." Conrad Sauvé President and CEO, Canadian Red Cross Quick Facts In September 2024, the Government of Canada introduces legislation (Bill C-76) to enable the transfer of land use planning and development authorities from Parks Canada to the Municipality of Jasper. This has facilitated land use planning and development in the long term. In the short term, Parks Canada and the Municipality of Jasper are working together to streamline and adjust Parks Canada's existing processes. Parks Canada supported all necessary processes for accelerating rebuild of Jasper in concrete ways, such as updated land use policies, expedited approvals for variances, reduced parking requirements, facilitated subdivision processes, simplified development application process, and reduced up front compliance deposit costs. Parks Canada made 4.25 hectares of land available for interim housing and secured over 300 interim housing units for Jasper residents. Initial occupancy started February 26, 2025. Currently, 500 individuals are occupying interim housing in Jasper. The Canadian Red Cross provides interim lodging management services for Jasper residents placed in units as part of the interim housing program. As part of their interim lodging management role, the Canadian Red Cross support tenant relations, managing leases, utility management and coordinating maintenance for sites.
